

Corporate Office:

PNB Pragati Towers, 2nd Floor, Plot No. C-9, G-Block,
Bandra Kurla Complex, Bandra (E), Mumbai - 400 051.
Tel: 022-26532745 Fax: 022-26532687
Email: mumbai_corporate@pnbisl.com
GST: 27AAECP9801F1ZE

Ref. No. EIKO/BSE/2023-24/23

Date: July 14, 2023

To,
The Manager
Listing Operations
BSE Limited
Dalal Street
Mumbai 400 001

Sub.: Proposed Rights Issue of Equity Shares of Eiko Lifesciences Limited (the "Company or Issuer").

ISSUE OF UPTO 55,44,178 PARTLY PAID - UP EQUITY SHARES WITH A FACE VALUE OF 10 EACH FOR CASH AT A PRICE OF 45 PER EQUITY SHARE AGGREGATING UP TO 2,494.88* LAKHS ON A RIGHTS BASIS TO ELIGIBLE SHAREHOLDERS IN THE RATIO OF 2 RIGHTS EQUITY SHARES FOR EVERY 3 FULLY PAID-UP EQUITY SHARE HELD ON THE RECORD DATE I.E., JULY 07, 2023.

*Assuming full subscription receipt of all Call Monies with respect to Rights Equity Shares. Subject to finalization of the Basis of Allotment

With respect to the Issue, this is to confirm that in accordance with the applicable regulations of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), the Company has issued the following public announcement.

Announcement as per Regulation 84(1) of SEBI ICDR Regulations, (the "Pre-Issue Advertisement") dated July 13, 2023 and published on July 14, 2023, disclosing the date of completion of dispatch of Abridged Letter of Offer and the Common Application Form and the procedure to subscribe to the Issue in brief.

The Pre-issue Advertisement was published in the following newspapers:

Sr. No	Newspapers	Language	Editions
1.	Business Standard	English	Nationwide
2.	Business Standard	Hindi	Nationwide
3.	Mumbai Lakshwadeep	Marathi	Regional

In relation to the aforementioned, please find enclosed copy of the Pre-Issue Advertisement dated July 13, 2023 and published on July 14, 2023 in the above-mentioned newspapers.

All capitalised terms used in this letter and not defined shall have the meaning assigned to such terms in the Letter of Offer.

We request you to take the above on record and trust that the same is in order.

Thanking you,
Yours sincerely,
For PNB Investment Services Ltd.

Mahesh P Peswani
Senior Vice President



This is only an advertisement for information purposes and not for publication, distribution, or release directly or indirectly outside India. This is not an announcement for the Offer Document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the Letter of Offer dated July 7, 2023 (the "Letter of Offer" or "LOF") filed with the Stock Exchange, namely BSE Limited ("BSE") and the Securities and Exchange Board of India ("SEBI").

EIKO LIFESCIENCES LIMITED

Eiko Lifesciences Limited ("Company" or "Issuer") was originally incorporated as "Narendra Investments (Delhi) Private Limited" at Delhi, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 07, 1977, issued by Registrar of Companies, Delhi & Haryana. The name of the Company has been changed from Narendra Investments (Delhi) Private Limited to Narendra Investments (Delhi) Limited pursuant to conversion under Registrar of Companies, Delhi & Haryana on March 05, 1982. The Company having by special resolution dated April 09, 2014, altered the provisions of Memorandum of Association with respect to the place of the Registered Office by changing it from the state of Delhi to the Maharashtra as confirmed by an order of Regional Director bearing the date August 19, 2014, vide certificate of registration of Regional Director order for change of state as certified dated September 16, 2014. The name of the Company has been changed from Narendra Investments (Delhi) Limited to Eiko Lifesciences Limited with effect from June 24, 2021, by the Registrar of Companies, Mumbai, Maharashtra. The Corporate Identification Number of our Company is L65993MH1977PLC258134. For further details about the Company, please refer to the section titled "General Information" beginning on page 30 of the Letter of offer.

Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India
Tel: +91 22 25438095; Email: investor.relations@eikolifesciences.com; Website: www.eikolifesciences.com
Contact Person: Mr. Jaid Ismail Kojar, CFO

PROMOTERS OF THE COMPANY: MR. LAXMIKANT RAMPRASAD KABRA AND MR. BHAVESH DHIRAJLAL TANNA FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF EIKO LIFESCIENCES LIMITED ONLY

ISSUE OF UPTO 55,44,178 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF EIKO LIFESCIENCES LIMITED ("EIKO" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 45 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 35 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹ 2,494.88* LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 2 (TWO) EQUITY SHARE FOR EVERY 3 (THREE) EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. FRIDAY JULY 07, 2023 (THE "ISSUE"). THE ISSUE PRICE IS 4.5 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 112 OF THE LETTER OF OFFER

*Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

ISSUE PROGRAMME		
ISSUE OPENS ON	LAST DATE FOR ON-MARKET RENUNCIATION*	ISSUE CLOSES ON**
MONDAY, JULY 17, 2023	THURSDAY, JULY 20, 2023	WEDNESDAY, JULY 26, 2023

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

***Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA *	Simple, Safe, Smart way of Application - Make use of it!!!
	*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below

PROCESS OF MAKING AN APPLICATION IN THE ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process, in the event the Shareholders are not able to utilize the ASBA facility for making an application despite their best efforts. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details refer to "Terms of the Issue - Process of Making an Application in the Issue" on page 113 of the Letter of Offer.

Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, Applications may be submitted at Designated Branches of the SCSBs. Further, in terms of the SEBI Circular CIR/CFD/DIL/1/2013 dated January 2, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSBs should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making Application in the Issue and clear demarcated funds should be available in such account for Applications.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the ISIN: IN9666Q01014; subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 124 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date i.e. Friday, July 07, 2023 are requested to provide relevant details (such as copies of self-attested PAN, client master list and details of address proof by way of uploading on Registrar website the records confirming the legal and beneficial ownership of their respective Equity Shares) not later than two Working Days prior to the Issue Closing Date i.e., Wednesday, July 26, 2023 in order to be eligible to apply for this Issue. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to the Company or the Registrar account is active to facilitate the aforementioned transfer.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE - PROCESS OF MAKING AN APPLICATION IN THE ISSUE" ON PAGE 113 OF THE LETTER OF OFFER.

PROCEDURE FOR MAKING OF AN APPLICATION THROUGH THE ASBA PROCESS: Shareholders are required to have an ASBA enabled bank account with an SCSB, prior to making the Application. Shareholders desiring to make an Application in this Issue may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/ electronic Application through the website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=34..>

Please note that subject to SCSBs complying with the requirements of the SEBI circular bearing reference number CIR/CFD/DIL/13/2012 dated September 25, 2012, within the periods stipulated therein, Applications may be submitted at the Designated Branches of the SCSBs. Further, in terms of the SEBI circular bearing reference number CIR/CFD/DIL/1/2013 dated January 2, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this Issue and clear demarcated funds should be available in such account for such an Application.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICES/ REFUND ORDERS" ON PAGE 134 OF THE LETTER OF OFFER.

Application by Eligible Equity Shareholders on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of Application Form as detailed above. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, Stock Exchange or the Lead Manager. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorizing such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that in terms of Regulation 78 of the SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholders including joint holders, in the same order and as per the specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

1. Name of our Issuer, being Eiko Lifesciences Limited; 2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository); 3. Registered Folio Number/ DP and Client ID No.; 4. Number of Equity Shares held as on Record Date; 5. Allotment option preferred - only Demat form; 6. Number of Rights Equity Shares entitled to; 7. Number of Rights Equity Shares applied for; 8. Number of Additional Rights Equity Shares applied for, if any; 9. Total number of Rights Equity Shares applied for within the Right Entitlements; 10. Total amount paid at the rate of ₹ 45/- per Rights Equity Share; 11. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 12. In case of NR Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO Account such as the account number, name, address and branch of the SCSB with which the account is maintained; 13. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Rights Equity Shares applied for pursuant to the Issue. Documentary evidence for exemption to be provided by the applicants; 14. Authorization to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); 16. An approval obtained from any regulatory authority, if required, shall be obtained by the Eligible Equity Shareholders and a copy of such approval from any regulatory authority, as may be required, shall be sent to the Registrar at:

Bigshare Services Pvt. Ltd.
Office No. S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Next to Ahura Centre, Andheri East, Mumbai - 400 093, Maharashtra, India.
Email Id: rightsissue@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Mr. Vijay Surana
SEBI Registration No: INR00001385

16. Additionally, all such Applicants are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

I/ We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction in compliance with Regulations, or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

I/ We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares is/ are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is/ are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements. "

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where a Shareholders submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

SELLING RESTRICTIONS: The distribution of the Letter of Offer, Abridged Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession the Letter of Offer, Abridged Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Abridged Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

NO OFFER IN THE UNITED STATES: The Rights Entitlements and the Rights Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any U.S. State Securities laws and may not be offered, sold, resold or otherwise transferred within the United States, except in a transaction exempt from the registration requirements of the securities act. The rights entitlements and equity shares referred to in the letter of offer are being offered in India, but not in the United States. The offering to which the Letter of offer relates is not, and under no circumstances is to be construed as, an offering of any equity shares or rights entitlements for sale in the United States or as a solicitation therein of an offer to buy any of the said securities. Accordingly, the letter of offer should not be forwarded to or transmitted in or into the United States at any time.

Neither our Company, nor any person acting on behalf of our Company, will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company, or any person acting on behalf of our Company, has reason to believe is, in the United States when the buy order is made. Envelopes containing an Application Form should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer under the Letter of Offer. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders and the

Abridged Letter of Offer, Application Form and the Rights Entitlement Letter will be dispatched to the Eligible Equity Shareholders who have provided an Indian address to our Company. Any person who acquires the Rights Entitlements and the Equity Shares will be deemed to have declared, represented, warranted and agreed, by accepting the delivery of the Letter of Offer, (i) that it is not and that, at the time of subscribing for the Equity Shares or the Rights Entitlements, it will not be, in the United States when the buy order is made; and (ii) is authorised to acquire the Rights Entitlements and the Equity Shares in compliance with all applicable laws, rules and regulations.

Our Company, in consultation with the Lead Manager, reserves the right to treat as invalid any Application Form which: (i) appears to our Company or its agents to have been executed in or dispatched from the United States of America; (ii) does not include the relevant certification set out in the Application Form headed "Overseas Shareholders" to the effect that the person accepting and/or renouncing the Application Form does not have a registered address (and is not otherwise located) in the United States, and such person is complying with laws of the jurisdictions applicable to such person in connection with the Issue, among others; (iii) where our Company believes acceptance of such Application Form may infringe applicable legal or regulatory requirements; or (iv) where a registered Indian address is not provided, and our Company shall not be bound to allot or issue any Equity Shares or Rights Entitlement in respect of any such Application Form.

None of the Rights Entitlements or the Equity Shares have been, or will be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws in the United States. Accordingly, the Rights Entitlements and Equity Shares are being offered and sold only outside the United States in compliance with Regulation S under the Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled in the Application Form or a plain paper Application is **Wednesday, July 26, 2023, i.e., Issue Closing Date**. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Bankers to the Issue or the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 133 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

ALLOTMENT OF THE EQUITY SHARES IN DEMATERIALIZED FORM: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialized form; and (ii) a demat suspense escrow account (namely, "EIKO-RIGHT ISSUE ESCROW ACCOUNT.") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in a demat suspense account pursuant to Regulation 39 of the SEBI Listing Regulations; or (b) Equity Shares held in the account of IEPF authority; or (c) the demat accounts of the Eligible Equity Shareholder which are frozen or details of which are unavailable with our Company or with the Registrar on the Record Date; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings or (f) non-institutional equity shareholders in the United States.

In accordance with the circular SEBI Circular SEBI/HO/CFD/DIL/2/CIR/P/2020/13 dated January 22, 2020, the credit of Rights Entitlement and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, the Rights Entitlements of the Physical Shareholders shall be credited in a suspense escrow demat account opened by our Company during the Issue Period. The Physical Shareholders are requested to furnish the details of their demat account to the Registrar not later than two Working Days prior to the Issue Closing Date to enable the credit of their Rights Entitlements in their demat accounts at least one day before the Issue Closing Date. The Rights Entitlements of the Physical Shareholders who do not furnish the details of their demat account to the Registrar not later than two Working Days prior to the Issue Closing Date, shall lapse. Further, pursuant to a press release dated December 3, 2018 issued by the SEBI, with effect from April 1, 2019, a transfer of listed Equity Shares cannot be processed unless the Equity Shares are held in dematerialized form (except in case of transmission or transportation of Equity Shares). Such resident Eligible Equity Shareholders must check the procedure for application by physical shareholders in the section entitled "Terms of the Issue - Procedure for Making of an Application by Eligible Equity Shareholders holding Equity Shares in physical form" and "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" beginning on pages 117 and 134 of the Letter of Offer respectively.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

LISTING: The existing Equity Shares of our Company are listed on the Stock Exchange. Our Company has received 'in-principle' approval from the BSE for listing the Rights Equity Shares to be allotted pursuant to the Issue through their letter dated May 05, 2023. Our Company will also make applications to BSE to obtain trading approvals for the Rights Entitlements as required under the SEBI circular bearing reference number SEBI/HO/CFD/DIL/2/CIR/P/2020/13 dated January 22, 2020. For the purpose of this Issue, the Designated Stock Exchange is BSE.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the Letter of Offer to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the Letter Of Offer. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 106 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of BSE" on page 107 of the Letter of Offer.

BANKER TO THE ISSUE AND REFUND BANK: Kotak Mahindra Bank Limited

MONITORING AGENCY: Since the size of the Issue is less than ₹ 10,000 Lakh, our Company is not required to appoint a monitoring agency as per Regulation 82(1) of the SEBI ICDR Regulations.

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICDR Regulations and SEBI Rights Issue Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispatched only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Abridged Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on July 10, 2023 by Registrar to the Issue, i.e. Bigshare Services Private Limited to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/ Beneficial Owners of the Company as on the Record date, i.e., Friday, July 07, 2023, in electronic form through e-mail on July 10, 2023, to the equity shareholders who have registered email-id and physically through speed/registered post on July 13, 2023.

Further, the Letter of Offer will be sent/dispatched to the Eligible Equity Shareholders who have provided Indian address and who have made request in this regard.

Investors can access the Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of a) our Company at www.eikolifesciences.com ; b) the Registrar to the Issue at www.bigshareonline.com; c) the Lead Manager at www.pnbisl.com and d) the Stock Exchange at www.bseindia.com.




Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., www.bigshareonline.com) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e., www.eikolifesciences.com).

Further, our Company along with the Lead Manager will undertake all adequate steps to reach out to the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: www.bigshareonline.com
- Updation of Indian address/ email address/ phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com
- Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

The Letter of offer is also available on the website of SEBI at www.sebi.gov.in

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
 <p>PNB INVESTMENT SERVICES LIMITED PNB Pragati Towers, 2nd Floor, Plot No. C-9, G-Block, BKC, Bandra (E), Mumbai - 400 051, Maharashtra, India Telephone: +91 22 2672 6259 Contact Person: Ms. Menka Jha/ Mr. Sukant Goel E-mail: menka@pnbisl.com/sukant@pnbisl.com Website: www.pnbisl.com Investor grievance: complaints@pnbisl.com SEBI Registration Number: INM000011617</p>	 <p>BIGSHARE SERVICES PRIVATE LIMITED Office No S6-2, 6th floor Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400093, Maharashtra, India. Tel: 022 - 6263 8200/22 Contact Person: Vijay Surana Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Investors Grievance E-mail: investor@bigshareonline.com SEBI Registration Number: INR000001385</p>
Chief Financial Officer	
 <p>Mr. Jaid Ismail Kojar EIKO LIFESCIENCES LIMITED Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India. Tel: +91 98929 87172; E-mail: investor.relations@eikolifesciences.com Website: www.eikolifesciences.com</p>	

Investors may contact the Registrar to the Issue or our Chief Financial Officer for any pre-issue or post- Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 112 of the Letter of Offer.

For Eiko Lifesciences Limited
S/-
Mr. Jaid Ismail Kojar
Chief Financial Officer

Date: July 13, 2023
Place: Mumbai

Eiko Lifesciences Limited is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated July 7, 2023 with SEBI and the Stock Exchange. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, the Stock Exchange, BSE Limited at www.bseindia.com. Company at www.eikolifesciences.com, website of the Registrar at www.bigshareonline.com and the website of the Lead Manager at www.pnbisl.com. Potential Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with SEBI and the Stock Exchange, including the section titled "Risk Factors" beginning on page 17 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The Letter of Offer does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

This is only an advertisement for information purposes and not for publication, distribution, or release directly or indirectly outside India. This is not an announcement for the Offer Document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the Letter of Offer dated **July 7, 2023 (the "Letter of Offer" or "LOF")** filed with the Stock Exchange, namely BSE Limited ("BSE") and the Securities and Exchange Board of India ("SEBI").

EIKO LIFESCIENCES LIMITED

Eiko Lifesciences Limited ("Company" or "Issuer") was originally incorporated as "Narendra Investments (Delhi) Private Limited" at Delhi, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 07, 1977, issued by Registrar of Companies, Delhi & Haryana. The name of the Company has been changed from Narendra Investments (Delhi) Private Limited to Narendra Investments (Delhi) Limited pursuant to conversion under Registrar of Companies, Delhi & Haryana on March 05, 1982. The Company having by special resolution dated April 09, 2014, altered the provisions of Memorandum of Association with respect to the place of the Registered Office by changing it from the state of Delhi to the Maharashtra as confirmed by an order of Regional Director bearing the date August 19, 2014, vide certificate of registration of Regional Director order for change of state as certified dated September 16, 2014. The name of the Company has been changed from Narendra Investments (Delhi) Limited to Eiko Lifesciences Limited with effect from June 24, 2021, by the Registrar of Companies, Mumbai, Maharashtra. The Corporate Identification Number of our Company is L65993MH1977PLC258134. For further details about the Company, please refer to the section titled "General Information" beginning on page 30 of the Letter of offer.

Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India
Tel: +91 22 25438095; **Email:** investor.relations@eikolifesciences.com; **Website:** www.eikolifesciences.com
Contact Person: Mr. Jaid Ismail Kojar, CFO

PROMOTERS OF THE COMPANY: MR. LAXMIKANT RAMPRASAD KABRA AND MR. BHAVESH DHIRAJAL TANNA FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF EIKO LIFESCIENCES LIMITED ONLY

ISSUE OF UPTO 55,44,178 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF EIKO LIFESCIENCES LIMITED ("EIKO" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 45 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 35 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹ 2,494.88* LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 2 (TWO) EQUITY SHARE FOR EVERY 3 (THREE) EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. FRIDAY JULY 07, 2023 (THE "ISSUE"). THE ISSUE PRICE IS 4.5 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 112 OF THE LETTER OF OFFER

*Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

ISSUE PROGRAMME

ISSUE OPENS ON	LAST DATE FOR ON-MARKET RENUNCIATION*	ISSUE CLOSES ON**
MONDAY, JULY 17, 2023	THURSDAY, JULY 20, 2023	WEDNESDAY, JULY 26, 2023

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

****Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA *

Simple, Safe, Smart way of Application - Make use of it!!!

*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below

PROCESS OF MAKING AN APPLICATION IN THE ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process, in the event the Shareholders are not able to utilize the ASBA facility for making an application despite their best efforts). Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA.. For details refer to "Terms of the Issue – Process of Making an Application in the Issue" on page 113 of the Letter of Offer.

Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, Applications may be submitted at Designated Branches of the SCSBs. Further, in terms of the SEBI Circular CIR/CFD/DIL/1/2013 dated January 2, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSBs should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making Application in the Issue and clear demarcated funds should be available in such account for Applications.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the ISIN: IN9666Q01014; subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue – Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 124 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date i.e. Friday, July 07, 2023 are requested to provide relevant details (such as copies of self-attested PAN, client master list and details of address proof by way of uploading on Registrar website the records confirming the legal and beneficial ownership of their respective Equity Shares) not later than two Working Days prior to the Issue Closing Date i.e., Wednesday, July 26, 2023 in order to be eligible to apply for this Issue. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to the Company or the Registrar account is active to facilitate the aforementioned transfer.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE – PROCESS OF MAKING AN APPLICATION IN THE ISSUE" ON PAGE 113 OF THE LETTER OF OFFER.

PROCEDURE FOR MAKING OF AN APPLICATION THROUGH THE ASBA PROCESS: Shareholders are required to have an ASBA enabled bank account with an SCSB, prior to making the Application. Shareholders desiring to make an Application in this Issue may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/ electronic Application through the website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedPsp=yes&inmId=34>.

Please note that subject to SCSBs complying with the requirements of the SEBI circular bearing reference number CIR/CFD/DIL/13/2012 dated September 25, 2012, within the periods stipulated therein, Applications may be submitted at the Designated Branches of the SCSBs. Further, in terms of the SEBI circular bearing reference number CIR/CFD/DIL/1/2013 dated January 2, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this Issue and clear demarcated funds should be available in such account for such an Application..

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICES/ REFUND ORDERS" ON PAGE 134 OF THE LETTER OF OFFER.

Application by Eligible Equity Shareholders on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of Application Form as detailed above. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, Stock Exchange or the Lead Manager. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that in terms of Regulation 78 of the SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholders including joint holders, in the same order and as per the specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

1. Name of our Issuer, being Eiko Lifesciences Limited;
2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
3. Registered Folio Number/ DP and Client ID No.;
4. Number of Equity Shares held as on Record Date;
5. Allotment option preferred - only Demat form;
6. Number of Rights Equity Shares entitled to;
7. Number of Rights Equity Shares applied for;
8. Number of Additional Rights Equity Shares applied for, if any;
9. Total number of Rights Equity Shares applied for within the Right Entitlements;
10. Total amount paid at the rate of ₹ 45/- per Rights Equity Share;
11. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
12. In case of NR Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO Account such as the account number, name, address and branch of the SCSB with which the account is maintained;
13. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Rights Equity Shares applied for pursuant to the Issue. Documentary evidence for exemption to be provided by the applicants;
14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB);
16. An approval obtained from any regulatory authority, if required, shall be obtained by the Eligible Equity Shareholders and a copy of such approval from any regulatory authority, as may be required, shall be sent to the Registrar at:

Bigshare Services Pvt. Ltd.
 Office No. S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Next to Ahura Centre, Andheri East, Mumbai – 400 093, Maharashtra, India.
 Email Id: rightsissue@bigshareonline.com
 Website: www.bigshareonline.com
 Contact Person: Mr. Vijay Surana
 SEBI Registration No: INR000001385

16. Additionally, all such Applicants are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

I/ We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction in compliance with Regulations, or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

I/ We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares is/ are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is/ are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements. "

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where a Shareholders submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

SELLING RESTRICTIONS: The distribution of the Letter of Offer, Abridged Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession the Letter of Offer, Abridged Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Abridged Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

NO OFFER IN THE UNITED STATES: The Rights Entitlements and the Rights Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any U.S. State Securities laws and may not be offered, sold, resold or otherwise transferred within the United States, except in a transaction exempt from the registration requirements of the securities act. The rights entitlements and equity shares referred to in the letter of offer are being offered in India, but not in the United States. The offering to which the Letter of Offer relates is not, and under no circumstances is to be construed as, an offering of any equity shares or rights entitlements for sale in the United States or as a solicitation therein of an offer to buy any of the said securities. Accordingly, the letter of offer should not be forwarded to or transmitted in or into the United States at any time.

Neither our Company, nor any person acting on behalf of our Company, will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company, or any person acting on behalf of our Company, has reason to believe is, in the United States when the buy order is made. Envelopes containing an Application Form should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer under the Letter of Offer. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders and the

Abridged Letter of Offer, Application Form and the Rights Entitlement Letter will be dispatched to the Eligible Equity Shareholders who have provided an Indian address to our Company. Any person who acquires the Rights Entitlements and the Equity Shares will be deemed to have declared, represented, warranted and agreed, by accepting the delivery of the Letter of Offer, (i) that it is not and that, at the time of subscribing for the Equity Shares or the Rights Entitlements, it will not be, in the United States when the buy order is made; and (ii) is authorised to acquire the Rights Entitlements and the Equity Shares in compliance with all applicable laws, rules and regulations.

Our Company, in consultation with the Lead Manager, reserves the right to treat as invalid any Application Form which: (i) appears to our Company or its agents to have been executed in or dispatched from the United States of America; (ii) does not include the relevant certification set out in the Application Form headed "Overseas Shareholders" to the effect that the person accepting and/or renouncing the Application Form does not have a registered address (and is not otherwise located) in the United States, and such person is complying with laws of the jurisdictions applicable to such person in connection with the Issue, among others; (iii) where our Company believes acceptance of such Application Form may infringe applicable legal or regulatory requirements; or (iv) where a registered Indian address is not provided, and our Company shall not be bound to allot or issue any Equity Shares or Rights Entitlement in respect of any such Application Form.

None of the Rights Entitlements or the Equity Shares have been, or will be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws in the United States. Accordingly, the Rights Entitlements and Equity Shares are being offered and sold only outside the United States in compliance with Regulation S under the Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled in the Application Form or a plain paper Application is **Wednesday, July 26, 2023, i.e., Issue Closing Date.** Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Bankers to the Issue or the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 133 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

ALLOTMENT OF THE EQUITY SHARES IN DEMATERIALIZED FORM: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "EIKO-RIGHT ISSUE ESCROW ACCOUNT.") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in a demat suspense account pursuant to Regulation 39 of the SEBI Listing Regulations; or (b) Equity Shares held in the account of IEPF authority; or (c) the demat accounts of the Eligible Equity Shareholder which are frozen or details of which are unavailable with our Company or with the Registrar on the Record Date; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings or (f) non-institutional equity shareholders in the United States.

In accordance with the circular SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the credit of Rights Entitlement and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, the Rights Entitlements of the Physical Shareholders shall be credited in a suspense escrow demat account opened by our Company during the Issue Period. The Physical Shareholders are requested to furnish the details of their demat account to the Registrar not later than two Working Days prior to the Issue Closing Date to enable the credit of their Rights Entitlements in their demat accounts at least one day before the Issue Closing Date. The Rights Entitlements of the Physical Shareholders who do not furnish the details of their demat account to the Registrar not later than two Working Days prior to the Issue Closing Date, shall lapse. Further, pursuant to a press release dated December 3, 2018 issued by the SEBI, with effect from April 1, 2019, a transfer of listed Equity Shares cannot be processed unless the Equity Shares are held in dematerialized form (except in case of transmission or transposition of Equity Shares). Such resident Eligible Equity Shareholders must check the procedure for application by physical shareholders in the section entitled "Terms of the Issue - Procedure for Making of an Application by Eligible Equity Shareholders holding Equity Shares in physical form" and "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" beginning on pages 117 and 134 of the Letter of Offer respectively.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

LISTING: The existing Equity Shares of our Company are listed on the Stock Exchange. Our Company has received 'in-principle' approval from the BSE for listing the Rights Equity Shares to be allotted pursuant to the Issue through their letter dated May 05, 2023. Our Company will also make applications to BSE to obtain trading approvals for the Rights Entitlements as required under the SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020. For the purpose of this Issue, the Designated Stock Exchange is BSE.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the Letter of Offer to SEBI shall not in any way be deemed or construed that SEBI has cleared or approved the Letter Of Offer. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 106 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the full text of the "Disclaimer Clause of BSE" on page 107 of the Letter of Offer.

BANKER TO THE ISSUE AND REFUND BANK: Kotak Mahindra Bank Limited

MONITORING AGENCY: Since the size of the Issue is less than ₹ 10,000 Lakh, our Company is not required to appoint a monitoring agency as per Regulation 82(1) of the SEBI ICDR Regulations.

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICDR Regulations and SEBI Rights Issue Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Abridged Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on July 10, 2023 by Registrar to the Issue, i.e. Bigshare Services Private Limited to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members' Beneficial Owners of the Company as on the Record date, i.e., Friday, July 07, 2023, in electronic form through e-mail on July 10, 2023, to electronic form through e-mail on July 10, 2023, to electronic form through e-mail on July 10, 2023, to electronic form through speed/registered post on July 13, 2023.

Further, the Letter of Offer will be sent/dispached to the Eligible Equity Shareholders who have provided Indian address and who have made request in this regard.

Investors can access the Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of a) our Company at www.eikolifesciences.com; b) the Registrar to the Issue at www.bigshareonline.com; c) the Lead Manager at www.pnbisl.com and d) the Stock Exchange at www.bseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., www.bigshareonline.com) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e., www.eikolifesciences.com).

Further, our Company along with the Lead Manager will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- a) Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: www.bigshareonline.com
- b) Updation of Indian address/ email address/ phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com
- c) Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com
- d) Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

The Letter of offer is also available on the website of SEBI at www.sebi.gov.in

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
 <p>PNB INVESTMENT SERVICES LIMITED PNB Pragati Towers, 2nd Floor, Plot No. C-9, G-Block, BKC, Bandra (E), Mumbai – 400 051, Maharashtra, India Telephone: +91 22 2672 6259 Contact Person: Ms. Menka Jha/ Mr. Sukant Goel E-mail: menka@pnbisl.com/sukant@pnbisl.com Website: www.pnbisl.com Investor grievance: complaints@pnbisl.com SEBI Registration Number: INM000011617</p>	 <p>BIGSHARE SERVICES PRIVATE LIMITED Office No S6-2, 6th floor Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai – 400093, Maharashtra, India. Tel: 022 – 6263 8200/22 Contact Person: Vijay Surana Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Investors Grievance E-mail: investor@bigshareonline.com SEBI Registration Number: INR000001385</p>
Chief Financial Officer	
 <p>EIKO LIFESCIENCES LIMITED Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India. Tel: +91 98929 87172; E-mail: investor.relations@eikolifesciences.com Website: www.eikolifesciences.com</p>	

Investors may contact the Registrar to the Issue or our Chief Financial Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 112 of the Letter of Offer.

For Eiko Lifesciences Limited

Sd/-
Mr. Jaid Ismail Kojar
Chief Financial Officer

Eiko Lifesciences Limited is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated July 7, 2023 with SEBI and the Stock Exchange. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, the Stock Exchange, BSE Limited at www.bseindia.com, Company at www.eikolifesciences.com, website of the Registrar at www.bigshareonline.com and the website of the Lead Manager at www.pnbisl.com. Potential Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with SEBI and the Stock Exchange, including the section titled "Risk Factors" beginning on page 17 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The Letter of Offer does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

This is only an advertisement for information purposes and not for publication, distribution, or release directly or indirectly outside India. This is not an announcement for the Offer Document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the Letter of Offer dated July 7, 2023 (the "Letter of Offer" or "LOF") filed with the Stock Exchange, namely BSE Limited ("BSE") and the Securities and Exchange Board of India ("SEBI").

EIKO LIFESCENCES LIMITED

Eiko Lifesciences Limited ("Company" or "Issuer") was originally incorporated as "Narendra Investments (Delhi) Private Limited" at Delhi, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 07, 1977, issued by Registrar of Companies, Delhi & Haryana. The name of the Company has been changed from Narendra Investments (Delhi) Private Limited to Narendra Investments (Delhi) Limited pursuant to conversion under Registrar of Companies, Delhi & Haryana on March 05, 1982. The Company having by special resolution dated April 09, 2014, altered the provisions of Memorandum of Association with respect to the place of the Registered Office by changing it from the state of Delhi to the Maharashtra as confirmed by an order of Regional Director bearing the date August 19, 2014, vide certificate of registration of Regional Director order for change of state as certified dated September 16, 2014. The name of the Company has been changed from Narendra Investments (Delhi) Limited to Eiko Lifesciences Limited with effect from June 24, 2021, by the Registrar of Companies, Mumbai, Maharashtra. The Corporate Identification Number of our Company is L65993MH1977PLC258134. For further details about the Company, please refer to the section titled "General Information" beginning on page 30 of the Letter of offer.

Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India
Tel: +91 22 25438095; **Email:** investor.relations@eikolifesciences.com; **Website:** www.eikolifesciences.com
Contact Person: Mr. Jaid Ismail Kojar, CFO

PROMOTERS OF THE COMPANY: MR. LAXMIKANT RAMPRASAD KABRA AND MR. BHAVESH DHIRAJLAL TANNA
FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF EIKO LIFESCENCES LIMITED ONLY

ISSUE OF UPTO 55,44,178 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF EIKO LIFESCENCES LIMITED ("EIKO" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 45 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 35 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹ 2,494.88* LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 2 (TWO) EQUITY SHARE FOR EVERY 3 (THREE) EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. FRIDAY JULY 07, 2023 (THE "ISSUE"). THE ISSUE PRICE IS 4.5 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 112 OF THE LETTER OF OFFER

**Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.*

ISSUE PROGRAMME		
ISSUE OPENS ON	LAST DATE FOR ON-MARKET RENUNCIATION*	ISSUE CLOSING ON**
MONDAY, JULY 17, 2023	THURSDAY, JULY 20, 2023	WEDNESDAY, JULY 26, 2023

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renounees on or prior to the Issue Closing Date.*

*****Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.*

ASBA *	<p>Simple, Safe, Smart way of Application - Make use of it!!!</p> <p><i>*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below</i></p>
---------------	--

PROCESS OF MAKING AN APPLICATION IN THE ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process, in the event the Shareholders are not able to utilize the ASBA facility for making an application despite their best efforts). Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA.. For details refer to "Terms of the Issue - Process of Making an Application in the Issue" on page 113 of the Letter of Offer.

Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, Applications may be submitted at Designated Branches of the SCSBs. Further, in terms of the SEBI Circular CIR/CFD/DIL/1/2013 dated January 2, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making Application in the Issue and clear demarcated funds should be available in such account for Applications.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the ISIN: IN9666Q01014; subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 124 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date i.e. Friday, July 07, 2023 are requested to provide relevant details (such as copies of self-attested PAN, client master list and details of address proof by way of uploading on Registrar website the records confirming the legal and beneficial ownership of their respective Equity Shares) not later than two Working Days prior to the Issue Closing Date i.e., Wednesday, July 26, 2023 in order to be eligible to apply for this Issue. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to the Company or the Registrar account is active to facilitate the aforementioned transfer.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE - PROCESS OF MAKING AN APPLICATION IN THE ISSUE" ON PAGE 113 OF THE LETTER OF OFFER.

PROCEDURE FOR MAKING OF AN APPLICATION THROUGH THE ASBA PROCESS: Shareholders are required to have an ASBA enabled bank account with an SCSB, prior to making the Application. Shareholders desiring to make an Application in this Issue may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/ electronic Application through the website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=34>.

Please note that subject to SCSBs complying with the requirements of the SEBI circular bearing reference number CIR/CFD/DIL/13/2012 dated September 25, 2012, within the periods stipulated therein, Applications may be submitted at the Designated Branches of the SCSBs. Further, in terms of the SEBI circular bearing reference number CIR/CFD/DIL/1/2013 dated January 2, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this Issue and clear demarcated funds should be available in such account for such an Application..

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICES/ REFUND ORDERS" ON PAGE 134 OF THE LETTER OF OFFER.

Application by Eligible Equity Shareholders on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of Application Form as detailed above. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, Stock Exchange or the Lead Manager. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that in terms of Regulation 78 of the SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholders including joint holders, in the same order and as per the specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

1. Name of our Issuer, being Eiko Lifesciences Limited;
2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
3. Registered Folio Number/ DP and Client ID No.;
4. Number of Equity Shares held as on Record Date;
5. Allotment option preferred - only Demat form;
6. Number of Rights Equity Shares entitled to;
7. Number of Rights Equity Shares applied for;
8. Number of Additional Rights Equity Shares applied for, if any;
9. Total number of Rights Equity Shares applied for within the Right Entitlements;
10. Total amount paid at the rate of ₹ 45/- per Rights Equity Share;
11. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
12. In case of NR Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO Account such as the account number, name, address and branch of the SCSB with which the account is maintained;
13. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Rights Equity Shares applied for pursuant to the Issue. Documentary evidence for exemption to be provided by the applicants;
14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB);
16. An approval obtained from any regulatory authority, if required, shall be obtained by the Eligible Equity Shareholders and a copy of such approval from any regulatory authority, as may be required, shall be sent to the Registrar at:

Bigshare Services Pvt. Ltd.
 Office No. S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Next to Ahura Centre, Andheri East, Mumbai - 400 093, Maharashtra, India.
 Email Id: rightsissue@bigshareonline.com
 Website: www.bigshareonline.com
 Contact Person: Mr. Vijay Surana
 SEBI Registration No: INR000001385

16. Additionally, all such Applicants are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

"I/ We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction in compliance with Regulations, or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

"I/ We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares is/ are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is/ are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

"I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where a Shareholders submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

SELLING RESTRICTIONS: The distribution of the Letter of Offer, Abridged Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession the Letter of Offer, Abridged Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Abridged Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

NO OFFER IN THE UNITED STATES: The Rights Entitlements and the Rights Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any U.S. State Securities laws and may not be offered, sold, resold or otherwise transferred within the United States, except in a transaction exempt from the registration requirements of the securities act. The rights entitlements and equity shares referred to in the letter of offer are being offered in India, but not in the United States. The offering to which the Letter of offer relates is not, and under no circumstances is to be construed as, an offering of any equity shares or rights entitlements for sale in the United States or as a solicitation therein of an offer to buy any of the said securities. Accordingly, the letter of offer should not be forwarded to or transmitted in or into the United States at any time.

Neither our Company, nor any person acting on behalf of our Company, will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company, or any person acting on behalf of our Company, has reason to believe is, in the United States when the buy order is made. Envelopes containing an Application Form should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer under the Letter of Offer. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders and the

Abridged Letter of Offer, Application Form and the Rights Entitlement Letter will be dispatched to the Eligible Equity Shareholders who have provided an Indian address to our Company. Any person who acquires the Rights Entitlements and the Equity Shares will be deemed to have declared, represented, warranted and agreed, by accepting the delivery of the Letter of Offer, (i) that it is not and that, at the time of subscribing for the Equity Shares or the Rights Entitlements, it will not be, in the United States when the buy order is made; and (ii) is authorised to acquire the Rights Entitlements and the Equity Shares in compliance with all applicable laws, rules and regulations.

Our Company, in consultation with the Lead Manager, reserves the right to treat as invalid any Application Form which: (i) appears to our Company or its agents to have been executed in or dispatched from the United States of America; (ii) does not include the relevant certification set out in the Application Form headed "Overseas Shareholders" to the effect that the person accepting and/or renouncing the Application Form does not have a registered address (and is not otherwise located) in the United States, and such person is complying with laws of the jurisdictions applicable to such person in connection with the Issue, among others; (iii) where our Company believes acceptance of such Application Form may infringe applicable legal or regulatory requirements; or (iv) where a registered Indian address is not provided, and our Company shall not be bound to allot or issue any Equity Shares or Rights Entitlement in respect of any such Application Form.

None of the Rights Entitlements or the Equity Shares have been, or will be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws in the United States. Accordingly, the Rights Entitlements and Equity Shares are being offered and sold only outside the United States in compliance with Regulation S under the Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled in the Application Form or a plain paper Application is **Wednesday, July 26, 2023, i.e., Issue Closing Date**. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Bankers to the Issue or the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 133 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5:00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

ALLOTMENT OF THE EQUITY SHARES IN DEMATERIALIZED FORM: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "EIKO-RIGHT ISSUE ESCROW ACCOUNT.") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in a demat suspense account pursuant to Regulation 39 of the SEBI Listing Regulations; or (b) Equity Shares held in the account of IEPF authority; or (c) the demat accounts of the Eligible Equity Shareholder which are frozen or details of which are unavailable with our Company or with the Registrar on the Record Date; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings or (f) non-institutional equity shareholders in the United States.

In accordance with the circular SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the credit of Rights Entitlement and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, the Rights Entitlements of the Physical Shareholders shall be credited in a suspense escrow demat account opened by our Company during the Issue Period. The Physical Shareholders are requested to furnish the details of their demat account to the Registrar not later than two Working Days prior to the Issue Closing Date to enable the credit of their Rights Entitlements in their demat accounts at least one day before the Issue Closing Date. The Rights Entitlements of the Physical Shareholders who do not furnish the details of their demat account to the Registrar not later than two Working Days prior to the Issue Closing Date, shall lapse. Further, pursuant to a press release dated December 3, 2018 issued by the SEBI, with effect from April 1, 2019, a transfer of listed Equity Shares cannot be processed unless the Equity Shares are held in dematerialized form (except in case of transmission or transposition of Equity Shares). Such resident Eligible Equity Shareholders must check the procedure for application by physical shareholders in the section entitled "Terms of the Issue - Procedure for Making of an Application by Eligible Equity Shareholders holding Equity Shares in physical form" and "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" beginning on pages 117 and 134 of the Letter of Offer respectively.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

LISTING: The existing Equity Shares of our Company are listed on the Stock Exchange. Our Company has received "in-principle" approval from the BSE for listing the Rights Equity Shares to be allotted pursuant to the Issue through their letter dated May 05, 2023. Our Company will also make applications to BSE to obtain trading approvals for the Rights Entitlements as required under the SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020. For the purpose of this Issue, the Designated Stock Exchange is BSE.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the Letter of Offer to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the Letter Of Offer. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 106 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of BSE" on page 107 of the Letter of Offer.

BANKER TO THE ISSUE AND REFUND BANK: Kotak Mahindra Bank Limited

MONITORING AGENCY: Since the size of the Issue is less than ₹ 10,000 Lakh, our Company is not required to appoint a monitoring agency as per Regulation 82(1) of the SEBI ICDR Regulations.

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICDR Regulations and SEBI Rights Issue Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Abridged Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on July 10, 2023 by Registrar to the Issue, i.e. Bigshare Services Private Limited to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/ Beneficial Owners of the Company as on the Record date, i.e., Friday, July 07, 2023, in electronic form through e-mail on July 10, 2023, to the equity shareholders who have registered email-id and physically through speed/registered post on July 13, 2023.

Further, the Letter of Offer will be sent/dispached to the Eligible Equity Shareholders who have provided Indian address and who have made request in this regard.

Investors can access the Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of a) our Company at www.eikolifesciences.com; b) the Registrar to the Issue at www.bigshareonline.com; c) the Lead Manager at www.pnbisl.com and d) the Stock Exchange at www.bseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., www.bigshareonline.com) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e., www.eikolifesciences.com).

Further, our Company along with the Lead Manager will undertake all adequate steps to reach out to the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- 1) Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: www.bigshareonline.com
- 2) Updation of Indian address/ email address/ phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com
- 3) Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com
- 4) Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

The Letter of offer is also available on the website of SEBI at www.sebi.gov.in

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
<p>PNB INVESTMENT SERVICES LIMITED PNB Pragati Towers, 2nd Floor, Plot No. C-9, G-Block, BKC, Bandra (E), Mumbai - 400 051, Maharashtra, India Telephone: +91 22 2672 6259 Contact Person: Ms. Menka Jha/ Mr. Sukant Goel E-mail: menka@pnbisl.com/sukant@pnbisl.com Website: www.pnbisl.com Investor grievance: complaints@pnbisl.com SEBI Registration Number: INM000011617</p>	<p>BIGSHARE SERVICES PRIVATE LIMITED Office No S6-2, 6th floor Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400093, Maharashtra, India. Tel: +91-6263 8200/22 Contact Person: Vijay Surana Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Investors Grievance E-mail: investor@bigshareonline.com SEBI Registration Number: INR000001385</p>
Chief Financial Officer	
<p>Mr. Jaid Ismail Kojar EIKO LIFESCENCES LIMITED Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India. Tel: +91 9829298712; E-mail: investor.relations@eikolifesciences.com Website: www.eikolifesciences.com</p>	

Investors may contact the Registrar to the Issue or our Chief Financial Officer for any pre-Issue or post- Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 112 of the Letter of Offer.

For Eiko Lifesciences Limited

Date: July 13, 2023

Place: Mumbai

Sd/-
Mr. Jaid Ismail Kojar
Chief Financial Officer

Eiko Lifesciences Limited is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated July 7, 2023 with SEBI and the Stock Exchange. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, the Stock Exchange, BSE Limited at www.bseindia.com, Company at www.eikolifesciences.com, website of the Registrar at www.bigshareonline.com and the website of the Lead Manager at www.pnbisl.com. Potential Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with SEBI and the Stock Exchange, including the section titled "Risk Factors" beginning on page 17 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The Letter of Offer does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.